Detalles de la búsqueda
1.
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Cancer
; 117(21): 5013-20, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21456017
2.
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Oncologist
; 15(9): 944-53, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20798196
3.
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Oncologist
; 15(2): 122-9, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20156908
4.
The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
Clin Pharmacol Drug Dev
; 7(3): 277-286, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024542
5.
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Curr Med Res Opin
; 27(12): 2245-52, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21992075
6.
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
J Clin Oncol
; 27(33): 5538-46, 2009 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19786658
Resultados
1 -
6
de 6
1
Próxima >
>>